Cambridge Cognition Holdings plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cambridge Cognition Holdings plc
In Vivo looks at some of the benefits and challenges created by decentralized clinical trials, how technology is being applied, and how regulators and researchers are working to prove the efficiency and cost-effectiveness of DCT trials compared to traditional clinical trials.
Kintsugi is developing an AI-driven software that analyzes voice to detect depression and anxiety, offering clinicians an early screening tool in call centers, telehealth and remote monitoring.
Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
- Digital Health
- Other Names / Subsidiaries
- Cambridge Cognition Ltd
- Cambridge Cognition Holdings Ltd
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.